Company Description
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.
It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs.
In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
The company sells its products under the JustCBD and Vessel brands, as well as through Phatebo. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
| Country | United States |
| Founded | 2019 |
| IPO Date | May 11, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Clifford Starke |
Contact Details
Address: 3406 SW 26th Terrace, Suite C-1 Fort Lauderdale, Florida 33132 United States | |
| Phone | 954 842 4989 |
| Website | floragrowth.com |
Stock Details
| Ticker Symbol | FLGC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001790169 |
| CUSIP Number | 339764102 |
| ISIN Number | CA3397642016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Clifford A. Starke | Chief Executive Officer and Director |
| Samuel Dorf Esq. | Executive Chairman of the Board |
| Dany Vaiman | Chief Financial Officer |
| Dr. Manfred Ziegler | Managing Director |
| Patrick Moloney | Head of Product Development |
| Aaron Atin | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | EFFECT | Notice of Effectiveness |
| Mar 25, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 24, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 21, 2025 | SCHEDULE 13G | Filing |
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |